Cathepsin D is a ubiquitous lysosomal protease with important functions in protein catabolism. Three forms of the enzyme are known: 52 kDa procathepsin D, a 48-kDa intermediate form and stable cathepsin D with a 34-kDa heavy and a 14-kDa light chain. Oestrogen induces cathepsin D expression in breast cancer cells (Rochefort et al, 1987) . The enzyme plays a key role in metastatic spread by promoting the destruction of normal tissue architecture and in tumour growth by the influence of growth factors (Westley and May, 1996) . The prognostic value of cathepsin D in breast cancer is still controversial. Although most authors agree that high cathepsin D levels have a negative prognostic impact, the prognostic value of cathepsin D in clinically relevant subgroups of breast cancer patients has not been established (Rochefort, 1996) . Furthermore, the importance of epithelial vs stromal expression of cathepsin D within the tumour is unclear. The prognostic value of cathepsin D expression in the various cell types within a tumour remains to be established in further investigations (Cardiff, 1994; Westley and May, 1996) .
The cytosolic assay is a well-standardized method for the quantification of enzyme expression. The immunohistochemical method is not yet established for standardized quantification. However, this method allows a differentiation between tumour, stromal and non-tumour epithelial cell expression of cathepsin D.
The aim of this study was to investigate the prognostic value of immunohistochemically detected cathepsin D expression in tumour vs stromal tissue of 103 patients with invasive ductal carcinomas of the breast. Furthermore, we examined whether different cut-off points of immunoreactivity, which have been reported in previous studies, influence the prognostic significance of cathepsin D.
Several histomorphological subtypes of breast cancer display distinct growth patterns and behaviours of invasion (Tavassoli, 1992) . In our study, we also examined the association between cathepsin D expression and the histomorphological subtypes infiltrating ductal cancer (IDC) with extensive intraductal component (EIC) and multifocal breast cancer.
MATERIAL AND METHODS
We investigated 103 paraffin-embedded tumour specimens from women with primary invasive ductal carcinoma of the breast at stages pTl and 2. During the period 1980-87, all patients with stage pT 1 tumours underwent primary surgical treatment, including conservative tumour excision, and radiotherapy and all patients with stage pT2 tumours underwent radical mastectomy and radiotherapy. Axillary dissection was performed in all patients. In patients with positive lymph node status, adjuvant chemotherapy was administered after radical surgery. Antioestrogenic agents were given in patients with positive oestrogen receptor status. The mean age of patients was 54 years (range 23-81 years). Forty-two patients were premenopausal, whereas 61 were post-menopausal. All sections tested were routine formalin-fixed paraffinembedded samples. Paraffin sections were soaked in xylene to remove paraffin and rehydrated in graded alcohol series (100% to 70%). To recover antigenicity, we used the 'Antigen Retrieval System' (BioGenex, San Ramon, CA, USA) twice for 5 min in a microwave (HM 146, Elektra Bregenz, Schwaz, Austria) on high power (650 W). The sections were then washed in 10 mm phosphate-buffered saline (PBS) (pH 7.6). The sections were incubated with cathepsin D antiserum at 1:300 dilution for 60 min at room temperature and then for a further 30 min with biotinylated antimouse and anti-rabbit link-antibody (Dako LSAB 2 Kit). After rinsing in PBS, the sections were coated with streptavidin conjugated to alkaline phosphatase for 10 min. The sections were rinsed in PBS, incubated with Fast Red chromogen (naphthol phosphate substrate in Tris buffer, 5 mg Fast Red chromogen tablets, BioGenex) and then washed in distilled water. The sections were finally counterstained with haematoxylin and mounted. The staining reaction was confined to the cytoplasm.
Control for the immunohistochemical reaction was performed once in every staining run. Localization of the immunohistochemical reaction and staining intensity was positive to the same degree in all positive controls. The positive control slide was prepared 
Statistical analysis
Where appropriate, results were analysed by the chi-squared test. We calculated the survival and recurrence-free interval probabilities by the product limit method of Kaplan and Meier (Kaplan and Meier, 1958) . Univariate analysis was assessed using the log-rank test. For multivariate analysis, the Cox proportional hazards model (Cox, 1972) was used to assess the independent effect of cathepsin D expression. The potential prognostic factor was added to a model of known prognostic factors: pathological stage, histological grade and lymph node status. The specific breast cancerrelated survival was used in all analyses. Recurrence-free interval was defined as the time elapsed between the primary surgical treatment and the first verified metastasis or recurrence. All P-values are results of two-sided tests. The BMDP statistical software system (BMDP Statistical Software, Los Angeles, CA, USA, 1990) was used. P-values < 0.05 were considered statistically significant.
RESULTS
Of the 103 IDCs of the breast studied, stage pT 1 was present in 59 tumours (57.3%) and pT2 in 44 tumours (42.7%). We found low-(GI), moderate-(G2) and high-grade (G3) in both the tumour and the surrounding stroma; high immunoreactivity was found in six of these cases (5.8%).
The statistical results of carcinomas with positive cathepsin D expression were compared with cases with high immunoreactivity. There was no difference in the statistical significance between both groups regarding the association of cathepsin D expression with established prognostic factors, IDC with EIC and multifocal tumours (Table 1) , and prognosis for overall survival and recurrence-free interval ( Table 2) .
The results of cathepsin D expression with tumour stage, grade, nodal status, oestrogen receptor status, IDC with EIC and multifocal tumours are presented in Table 1 . Data from the univariate and multivariate analysis regarding overall survival and recurrence-free interval are shown in Table 2 . The number of patients was too small to consider pre-and postmenopausal or lymph nodepositive or -negative patients in a subgroup analysis. The survival distribution function grouped by cathepsin D epithelial tumour expression is shown in Figure 1 .
DISCUSSION
Most biochemical studies of cathepsin D in breast cancer show that elevated total tumour cathepsin D is an adverse prognostic factor. Subgroup analysis regarding node-negative and node-positive tumours yielded controversial results (Spyratros et al, 1989; Thorpe et al, 1989; Tandon et al, 1990; Westley and May, 1996) . The cytosolic assay is an established method for quantification of total enzyme expression without differentiation between benign or malignant, epithelial or stromal cell types. During recent years the importance of the tumour cell stroma in the process of breast cancer invasion has become more evident. Several proteases have been shown to be active in stromal cells of malignant tumours (Joensuu et al, 1995) . In breast cancer, stromal cells such as tumour-associated macrophages can overexpress cathepsin D along with epithelial tumour cells. Immunohistochemistry is a precise method to localize the expression of cathepsin D, but there is no general agreement about the results of immunohistochemically detected cathepsin D expression in breast cancer (Cardiff, 1994; Westley and May, 1996) . Therefore, the comparison of data on cathepsin D, measured by cytosolic assay and immunohistochemistry, must be interpreted with caution (Rochefort, 1996) .
Although most of the immunohistochemical studies reported immunostaining of macrophages in breast cancer, only a few of them regarded stromal cathepsin D expression as relevant for the patients' prognosis. Henry et al (1990) were the first group to describe high levels of cathepsin D expression in stromal macrophages of breast cancer patients. In this study, it was noted that stromal cells contribute significantly to the levels of cathepsin D in tumour cytosol. However, the prognostic value of enzyme expression in macrophages was not analysed (Henry et al, 1990) .
A number of studies have reported a poor prognosis for patients with cathepsin D expression in an epithelial tumour. Winstanley et al ( 1993) showed a prognostic difference in patients, depending on node-positive or node-negative status. Another study analysed cathepsin D tumour expression in node-negative cases and found a significantly poorer prognosis regarding relapse-free and overall survival in patients with cathepsin D-expressing tumours (Isola et al, 1993) . Kandalaft et al (1993) investigated cathepsin D tumour expression in both node-positive and -negative patients and found only a trend to poor prognosis for overall survival in node-positive cases.
More recent studies have separately analysed the prognostic value of cathepsin D expression in tumour cells and stroma. Two studies reported no prognostic significance for overall survival regarding tumour expression of cathepsin D, but decreased survival in the entire group of patients with increased stromal expression (Joensuu et al, 1995; O'Donoghue et al, 1995) . Nadji et al ( 1996) showed an association of stromal cathepsin D expression and shorter disease-free and overall survival in node-negative cases. Tetu et al (1993) found a trend for reduced relapse-free survival in a study restricted to node-positive patients. Gohring et al (1996) took immunoreaction in tumour cells and tumour-infiltrating macrophages into account and showed a significant correlation of cathepsin D expression with clinical outcome in node-negative, but not in node-positive, patients. Other studies, examining either both tumour and stromal or only tumour cathepsin D expression, did not find any association with diseasefree or overall survival (Domagala et al, 1992; Armas et al, 1994) .
In our study, cathepsin D expression in the epithelial tumour shows a poor prognosis for overall survival and recurrence-free interval in the univariate analysis. Stromal cathepsin D expression had no prognostic impact. However, tumour cathepsin D expression had no independent prognostic value in the multivariate analysis with established prognosticators.
A relationship between cathepsin D expression and well-established prognostic factors, such as tumour stage, differentiation and oestrogen receptor status, has been described in various studies. The correlation with nodal status shows more controversial results and should be examined in future investigations because of its strong prognostic value (Westley and May, 1996) . In our study, tumour cathepsin D expression was associated with tumour stage and differentiation but not with lymph node or oestrogen receptor status.
A variety of scoring methods have been used to assess the immunohistochemical reaction of cathepsin D expression:
histoscores on the basis of intensity and number of stained cells (Kandalaft et al, 1993) , assessment of the proportion of cells staining (Tetu et al, 1993) and assessment of overall positivity (Henry et al, 1990; Isola et al, 1993; Winstanley et al, 1993; O'Donoghue et al, 1995) . Studies assessing overall positivity chose different cut-off points ranging from 10% (Isola et al, 1993) to 25% (O'Donoghue et al, 1995) for positive cathepsin D immunoreactivity. To allow comparison of our data with recent studies, we have used two cut-off points (10% and 30%). Our study shows that different cut-off levels of positive cathepsin D expression have no influence on the statistical significance of the prognostic value regarding cathepsin D expression in breast cancer.
Histological subtypes of IDC of the breast have an important influence on therapy because of their unusual growth pattern. IDC with EIC and multifocal tumours of the breast are reported to be predictors of local recurrence after conservative surgery and radiotherapy (Tavassoli, 1992; Schnitt et al, 1984) . These subtypes seem to have a different prognostic value when compared with no otherwise specified (NOS) IDCs (Silverberg and Chitale, 1973; Dawson, 1993) . Cathepsin D plays an important role in promoting the breakdown of the basal membrane and degrading the extracellular matrix. The enzyme also shows an effect on cell proliferation by growth stimulation (Westley and May, 1996) . In our study, cathepsin D expression had no association with histomorphological subtypes, e.g. IDC with EIC or multifocal tumours.
In conclusion, our results support the assumption that stromal cathepsin D expression has no prognostic impact irrespective of the staining intensity. This is also underlined by the fact that stromal cathepsin D expression is not correlated with histomorphological tumour subtypes displaying pronounced growth patterns. Although we have found that epithelial cathepsin D expression is associated with a short overall and disease-free survival, it does not yield additional prognostic information in a multivariate model with established prognosticators.
